Jagsonpal Pharmaceuticals Limited

Financial Results Overview

Standalone Performance (Quarter ended September 30, 2026):

  • Revenue from operations: ₹813.75 million (Q2 FY2026: ₹744.65 million)
  • Other Income: ₹22.31 million (Q2 FY2026: ₹30.27 million)
  • Total Income: ₹836.06 million (Q2 FY2026: ₹774.92 million)
  • Profit Before Tax: ₹172.82 million
  • Profit After Tax: ₹123.88 million (Q2 FY2026: ₹111.74 million)
  • Basic EPS: ₹1.91 (Q2 FY2026: ₹1.88)
  • Diluted EPS: ₹1.87 (Q2 FY2026: ₹1.87)

Standalone Performance (Half year ended September 30, 2026):

  • Revenue from operations: ₹1,636.07 million (H1 FY2026: ₹1,500.77 million)
  • Other Income: ₹50.64 million (H1 FY2026: ₹58.52 million)
  • Total Income: ₹1,686.71 million (H1 FY2026: ₹1,559.29 million)
  • Profit Before Tax: ₹345.08 million (H1 FY2026: ₹312.41 million)
  • Profit After Tax: ₹256.71 million (H1 FY2026: ₹235.96 million)
  • Basic EPS: ₹3.91 (H1 FY2026: ₹3.50)
  • Diluted EPS: ₹3.85 (H1 FY2026: ₹3.45)

Consolidated Performance (Quarter ended September 30, 2026):

  • Revenue from operations: ₹965.35 million
  • Other Income: ₹22.49 million
  • Profit After Tax: ₹122.87 million
  • Basic EPS: ₹1.86
  • Diluted EPS: ₹1.83

Consolidated Performance (Half year ended September 30, 2026):

  • Revenue from operations: ₹1,786.03 million
  • Other Income: ₹50.84 million
  • Profit After Tax: ₹254.76 million
  • Basic EPS: ₹3.86
  • Diluted EPS: ₹3.81

Key Corporate Events

1. Employee Stock Options: Granted 120,000 stock options under Employee Stock Option Plan 2022 and allotted 223,775 equity shares on exercise of vested stock options.

2. Dividend Payment: Paid final dividend of ₹4 per equity share (face value ₹2) totaling ₹263.83 million for FY2026, approved at AGM held on September 18, 2026.

3. Acquisition: Acquired 85% equity stake in Aequitas Healthcare Private Limited for ₹208 million effective July 1, 2026. Transaction involved professional fees of ₹2.35 million recognized as exceptional item. Goodwill of ₹86 million recognized on acquisition.

4. Business Transfer Agreement: Entered into BTA with Group Pharmaceuticals Limited on September 23, 2026 for acquisition of Wellness Portfolio via slump sale. Closing formalities completed in October 2026, no financial impact in Q2 results.

5. Share Buyback: Completed buyback of equity shares including related expenses totaling ₹401.14 million.

Capital Structure Changes

  • Paid-up equity share capital (standalone): ₹132.12 million as of September 30, 2026 (₹133.93 million as of March 31, 2026)
  • Reserves excluding revaluation reserves: ₹2,305.89 million as of September 30, 2026 (₹2,627.79 million as of March 31, 2026)

Cash Flow Highlights (Half year ended September 30, 2026)

Standalone:

  • Net cash from operating activities: ₹261.93 million
  • Net cash from investing activities: ₹455.53 million
  • Net cash used in financing activities: ₹626.95 million
  • Net increase in cash: ₹90.51 million

Consolidated:

  • Net cash from operating activities: ₹254.65 million
  • Net cash from investing activities: ₹454.96 million
  • Net cash used in financing activities: ₹619.57 million
  • Net increase in cash: ₹90.04 million

Notes to Financial Results

  • Prepared in accordance with Ind AS 34 and SEBI Listing Regulations
  • Impact of New Labour Codes resulted in additional employee benefit expense of ₹20.79 million recognized as exceptional item in FY2026
  • Company operates in single reportable business segment of pharmaceutical products
  • Consolidated results include Aequitas Healthcare Private Limited as subsidiary from July 1, 2026